独特优势赋能：期货活水+制度政策双重支撑

Core Insights - The capital market has entered a recovery phase since September 24, 2024, with the Hang Seng Biotechnology Index showing a cumulative increase of 78.6%, outperforming the Hong Kong Stock Connect Innovative Drug Index, indicating high elasticity and a strong Sharpe ratio [1][4]. Performance Metrics - Annualized Return: Hang Seng Biotechnology Index at 59.42%, compared to 57.50% for Hong Kong Stock Connect Innovative Drug Index [3]. - Annualized Volatility: Hang Seng Biotechnology Index at 41.03%, slightly lower than the Hong Kong Stock Connect Innovative Drug Index at 42.66% [3]. - Maximum Drawdown: Hang Seng Biotechnology Index at -27.55%, which is comparable to other indices [3]. - Sharpe Ratio: Hang Seng Biotechnology Index leads with a ratio of 1.45, outperforming other related indices [3][4]. - Cumulative Return since 2025: Hang Seng Biotechnology Index at 67.50%, again showing superiority over similar indices [4]. Index Characteristics - The Hang Seng Biotechnology Index is the only Hong Kong medical theme index with index futures, enhancing investment strategies and liquidity [6][7]. - The introduction of index futures in November 2025 is expected to improve liquidity and attract more investment [6][7]. - The index has shown strong trading activity, with an average daily turnover of approximately 16 billion yuan in 2015 [6]. Regulatory Framework - The 18A system in Hong Kong provides a unique listing channel for unprofitable biotech companies, enhancing the attractiveness of the Hong Kong market for international capital [9][11]. - Over 70 biotech companies have listed under the 18A system, which is more flexible compared to similar regulations in other markets [11]. Investment Opportunities - The Hang Seng Biotechnology ETF (Code: 520933) is positioned as an optimal choice for investors looking to participate in the biotech sector with lower entry barriers [12].